Immix Biopharma Inc./$IMMX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
Ticker
$IMMX
Sector
Primary listing
Employees
21
Headquarters
Website
IMMX Metrics
BasicAdvanced
$617m
-
-$0.89
-
-
Price and volume
Market cap
$617m
52-week high
$11.61
52-week low
$1.87
Average daily volume
1.1m
Financial strength
Current ratio
8.755
Quick ratio
8.594
Long term debt to equity
1.081
Total debt to equity
1.23
Profitability
EBITDA (TTM)
-35.778
Effective tax rate (TTM)
-0.08%
Management effectiveness
Return on assets (TTM)
-38.97%
Return on equity (TTM)
-74.47%
Valuation
Price to book
5.55
Price to tangible book (TTM)
5.55
Price to free cash flow (TTM)
-10.624
Free cash flow yield (TTM)
-9.41%
Free cash flow per share (TTM)
-0.832
Growth
Earnings per share change (TTM)
26.89%
3-year earnings per share growth (CAGR)
9.62%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs